跳至主要内容
临床试验/EUCTR2019-003150-86-GB
EUCTR2019-003150-86-GB进行中(未招募)1 期

A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses - Duration of Ameluz Application in Acral Actinic Keratoses

Royal Cornwall Hospitals NHS Trust0 个研究点目标入组 74 人开始时间: 2019年11月5日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
74

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) Patient has given written informed consent.
  • 2) Male or non-pregnant, non-lactating female.
  • 3) Age greater than 18 years.
  • 4) AK lesions on arms, hands, legs or feet that are practical to treat with PDT.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 0
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • 1) Lesions with a clinical diagnosis of Bowen’s disease, superficial, morphoeic or nodular basal cell carcinoma, squamous cell carcinoma, or melanoma as they are not the types of lesions required for investigation.
  • 2) Any disease which is caused or exacerbated by light, including systemic lupus erythematosus, porphyria, actinic reticuloid or xeroderma pigmentosum. Part of the clinical study will be the use of light-imaging system so any condition, which is sensitive to such instruments, will be excluded.
  • 3) For males and females of childbearing potential, the lack of adequate contraceptive precaution. Female patients should practice strict birth control (oestrogen-containing oral contraceptives or an IUD) throughout the trial. Only post-menopausal women (at least 2 years since the onset of the menopause) and women who have had a hysterectomy are exempt from the requirements to use birth control.
  • 4) Treatment in the previous 45 days with any cryotherapy, topical treatments for AK, experimental compound, an iron chelating agent, radiotherapy, chemotherapy or with any light activated therapy or any other medication, which may render the patient light sensitive (e.g. PUVA).
  • 5) Photodynamic therapy treatment in the previous 90 days.
  • 6) Co-existing ophthalmic disease likely to require slit lamp examination within 30 days of PDT treatment.
  • 7) Known allergies to porphyrins.
  • 8) Patients not able to comply with study requirements.

研究者

相似试验